Navigation Links
University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
Date:8/6/2012

PHILADELPHIA In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies. The agreement, which follows a Penn research team's 2011 publication of breakthrough results in several chronic lymphocytic leukemia patients treated with this personalized immunotherapy technique, paves the way for pivotal studies that have the potential to expand the use of CAR therapies for additional cancers.

The new alliance represents a marquee achievement in Penn's commitment to translational science aimed at expediting the process of bringing novel therapies to patients. Together, Penn and Novartis will build a first-of-its-kind Center for Advanced Cellular Therapies (CACT) on the Penn campus in Philadelphia -- a venture which will bring full circle the 1960 discovery of the Philadelphia chromosome, the first description of a chromosome abnormality that causes cancer. The center will be devoted to the discovery, development and manufacturing of adoptive T cell immunotherapies through a joint research and development program led by scientists and clinicians from Penn, Novartis, and the Novartis Institutes for Biomedical Research.

"Penn's intellectual resources, combined with a pharmaceutical industry leader like Novartis, offer a powerful symbiotic relationship in our mutual goal of finding more effective treatments for cancer," said J. Larry Jameson, MD, PhD, dean of the Perelman School of the Medicine at the University of Pennsylvania and executive vice president for the Health System. "With our shared commitment to rapidly advancing new therapies and cures, this new alliance will provide the support for the essential clinical trials with engineered T cells, which could open doors for use of promising treatment options for many cancer patients who have reached the end of currently available treatments."

Under the terms of the agreement, Penn grants Novartis an exclusive worldwide license to the technologies used in an ongoing trial of patients with chronic lymphocytic leukemia (CLL) as well as future CAR-based therapies developed through the collaboration. Novartis will invest in the establishment of the CACT and future research of the technology. Additional milestone and royalty payments to Penn are also part of the agreement.

In August 2011, the Penn team detailed the results of an early trial utilizing the modified T cell approach among a small group of advanced chronic lymphocytic leukemia patients in the New England Journal of Medicine and Science Translational Medicine. The findings including reports on two patients who remained in remission more than a year after their treatment served as the first demonstration of the use of gene transfer therapy to create T cells aimed at battling cancerous tumors. The protocol involves removing a patient's cells and modifying them in Penn's vaccine production facility, then infusing the new cells back into the patient's body following chemotherapy to attack their remaining tumors. Thus far, the study has involved only patients whose cancers have not responded to traditional therapy. These patients' only remaining treatment options would have been a bone marrow transplant, a procedure which carries a mortality risk of at least 20 percent.

"Our early results in patients treated with chimeric antigen receptors represent two decades of investment and perseverance in our effort to treat cancer in an entirely new way, combining a highly targeted cell-based therapy with the might of a patient's own immune system," said the study's leader, Carl June, MD, a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of Translational Research at Penn's Abramson Cancer Center. "By joining forces with Novartis, we will now have the resources and space to expand our research in new directions that we hope will change the way cancers of all kinds are treated."

Although further studies are needed to explore the long-term viability of the treatment, June's team showed that in the patients studied so far, months after infusion, the new cells had multiplied throughout the patients' bodies and were capable of continuing their "seek-and-destroy" mission against cancerous cells.

In addition to continued trials in CLL, Penn also has engineered T cell trials underway for other leukemias as well as lymphoma, mesothelioma, myeloma, and neuroblastoma. To read more about the early results of Penn's work using the new treatment approach and watch a video of June and his co-investigators discussing the research, visit Penn Medicine's online press kit.


'/>"/>
Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. University of Cincinnati researchers win $3.7M grant from US Department of Defense
2. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
3. Rice University student engineers automate limb lengthening for kids
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Neuropsychologist receives University of Houstons highest faculty honor
6. University of Houston Graduate College of Social Work announces partnership with MD Anderson
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. University of Minnesota startup to treat challenging bacterial infection
9. University studies and career expectations of medical students
10. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
11. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... (PRWEB) , ... December 02, 2019 , ... ... unsurpassed efficiency and flexibility to the Sterile Processing Department. The elegant design provides ... clean. The P1000 has downward sliding doors that allow for manual loading that ...
(Date:11/30/2019)... ... November 29, 2019 , ... ... and honored customs, teachers aren’t focusing on the potential for academic backslide but ... picking up their textbooks or logging into GoogleClassroom as often during the break ...
(Date:11/27/2019)... , ... November 27, 2019 , ... ... environment—targeting the human sense of smell has a far deeper reach. Aroma travels ... essence can have hugely beneficial effects on both consumers and workers. The human ...
(Date:11/23/2019)... ... November 22, 2019 , ... ... designed to improve the quality and safety of medical diagnoses. Bipartisan legislation, Improving ... Ben Ray Luján (D-NM) and Rep. Gus Bilirakis (R-FL) on November 13. , ...
(Date:11/23/2019)... (PRWEB) , ... November 23, 2019 , ... The potential ... complex information, store memories, as well as strategize and plan. In a world of ... to deliberate carefully before taking action should be praised, should it not? But even ...
Breaking Medicine News(10 mins):
(Date:11/30/2019)... ... November 29, 2019 , ... ... screening, that uses deep learning algorithms to automatically detect potential breast cancer in ... Society of North America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, South Hall ...
(Date:11/30/2019)... ... November 29, 2019 , ... In the United States, we regard ... reviews, and media, there is no shortage of phenomenal restaurants for guests to visit. ... talent in the world. Christian Bowman, Chef to NBA All-Stars and celebrities, is a ...
(Date:11/27/2019)... Calif (PRWEB) , ... November 27, 2019 , ... ... with Urea to help those suffering from extreme dry skin disorders. Urea ... This holy grail ingredient provides intensive hydration to restore moisture balance for consumers ...
Breaking Medicine Technology: